Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Idorsia Ltd
  6. Summary
    IDIA   CH0363463438

IDORSIA LTD

(IDIA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
25.62(c) 25.84(c) 26.86(c) 26.94(c) 26.72(c) Last
343 464 358 035 456 510 319 664 231 910 Volume
-0.93% +0.86% +3.95% +0.30% -0.82% Change
More quotes
Financials
Sales 2021 34,9 M 38,8 M 38,8 M
Net income 2021 -642 M -714 M -714 M
Net Debt 2021 416 M 463 M 463 M
P/E ratio 2021 -6,83x
Yield 2021 -
Sales 2022 105 M 117 M 117 M
Net income 2022 -630 M -701 M -701 M
Net Debt 2022 675 M 751 M 751 M
P/E ratio 2022 -7,42x
Yield 2022 -
Capitalization 4 465 M 4 966 M 4 969 M
EV / Sales 2021 140x
EV / Sales 2022 48,9x
Nbr of Employees 650
Free-Float 63,4%
More Financials
Company
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan... 
More about the company
Ratings of Idorsia Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about IDORSIA LTD
06/09IDORSIA  : Daridorexant Shows Sleep Improvement in Insomnia Patients
MT
06/09PRESS RELEASE  : Idorsia to present new Phase 3 data on daridorexant in insomnia..
DJ
06/09Idorsia to present new Phase 3 data on daridorexant in insomnia at SLEEP 2021
GL
05/25GLOBAL MARKETS LIVE : Vonovia, Amazon, Xiaomi, Apple, Huawei...
05/25IDORSIA  : Wins EU Approval For Ponvory In Relapsing Multiple Sclerosis
MT
05/25IDORSIA  : European Commission approves Ponvory (ponesimod) for the treatment of..
PU
05/25PRESS RELEASE  : European Commission approves Ponvory (ponesimod) for the treatm..
DJ
05/12IDORSIA  : holds its Annual General Meeting of Shareholders
AQ
05/12PRESS RELEASE  : Idorsia holds its Annual General Meeting of Shareholders
DJ
04/22IDORSIA  : Q1 Loss Narrows on Positive Financial Income
MT
04/22PRESS RELEASE  : Idorsia announces financial -3-
DJ
04/22PRESS RELEASE : Idorsia announces financial -2-
DJ
04/22PRESS RELEASE : Idorsia announces financial results for the first quarter 2021 -..
DJ
04/01PRESS RELEASE  : Idorsia issues Notice of the 2021 -2-
DJ
04/01PRESS RELEASE : Idorsia issues Notice of the 2021 Annual General Meeting of Shar..
DJ
More news
News in other languages on IDORSIA LTD
06/09Aktien Schweiz Vorbörse: Kaum verändert - Mehrheit der Titel notiert tiefer
06/09Bourse Zurich: vers une timide poursuite de la marche en avant
06/09Morning Briefing - Markt Schweiz
06/09Idorsia stellt weitere Daten zu Schlafmittel Daridorexant an Fachkongress vor
06/09GlobeNewswire/Idorsia to present new Phase 3 data on daridorexant in insomnia..
More news
Analyst Recommendations on IDORSIA LTD
More recommendations
Chart IDORSIA LTD
Duration : Period :
Idorsia Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IDORSIA LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 30,42 CHF
Last Close Price 26,72 CHF
Spread / Highest target 49,7%
Spread / Average Target 13,8%
Spread / Lowest Target -28,9%
EPS Revisions
Managers and Directors
NameTitle
Jean-Paul Clozel Chief Executive Officer & Director
André C. Muller Chief Financial Officer & Executive Vice President
Mathieu Simon Chairman
Guy Braunstein Executive VP & Head-Global Clinical Development
Martine Clozel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
IDORSIA LTD4.70%4 966
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966